Skip to main content

Viridian Therapeutics, Inc.DE 8-K, filed Nov 9, 2026

Viridian Therapeutics, Inc.DE (VRDN)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Viridian Therapeutics, Inc.DE filed this 8-K on November 9, 2026.

Viridian Therapeutics reported positive phase 1 results for VRDN-008, including 74% peak IgG reduction and an extended half-life of 15–18 days. It plans a pivotal MG trial in mid-2027, pending regulatory feedback. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits